Market TodayThemes and Stocks SummaryThematic Stock SearchCrypto SummaryFAQAbout
NTLA - Intellia Therapeutics Inc
-1.51(-3.63%)9:00:00 PM 1/30/2023
Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron. Intellia Therapeutics was founded in May 2014 to develop biopharmaceuticals using CRISPR.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 


Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.


  • MACD is crossing MACD signal line at 0.8. MACD crossing signal line is bullish signal.
Stock Statistics
PE Ratio-6.8
PEG Ratio-1.1
P/S (ttm)100.4
Earning Growth (QoQ)
Revenue Growth (QoQ)
Short %12%
Held by Institutions %88%
1 Day Vol Adjusted Return-0.7
1 Month Vol Adjusted Return4.1
3 Month Vol Adjusted Return-5.4
6 Month Vol Adjusted Return-8.4
20 Days SMA Price ZScore1.3
50 Days SMA Price ZScore0.0
12 -26 Days PPO-0.0
1 Month Average Short Volume Ratio39.1
1 Day Volume Change ZScore-0.3
1 Month Daily Vol4.8
Related Topics
leak data

Related Peers

Stock news

    3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later

    To many investors, gene editing sounds like the plot of a science fiction movie. The concept of being able to edit our DNA to cure genetic diseases is quite unbelievable, and the upside of gene editing to treat rare diseases is impressive. However, many gene editing stocks are making waves, looking to advance toward eradicating cancer and other serious illnesses. But ever since 2012, gene editing has been a reality, at least in terms of having the technology needed to edit genes. Don’t get me wr

    3 Gene Editing Stocks With the Best Long-Term Potential

    Gene editing stocks present themselves as one of the more lucrative investments in the healthcare sector. Gene editing, a revolutionary take on the science of genetic engineering, has the potential to countless lives around the globe. By introducing genetic material into cells, scientists can correct genetic abnormalities in a way never seen before. With the potential for vast improvements, gene therapy and gene editing are promising modern biotechnology forms.InvestorPlace - Stock Market News,

    Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

    Cathie Wood is beating the market again so far in 2023, and that leaves growth investors wondering if she can recapture her 2020 performance in a bottle. Ark puts out daily transaction reports, so we know what Wood is buying and selling. Tesla bears think they're winning with the stock down 65% since hitting all-time highs in late 2021.

    Does Intellia Therapeutics, Inc. (NTLA) Have the Potential to Rally 185.4% as Wall Street Analysts Expect?

    The consensus price target hints at an 185.4% upside potential for Intellia Therapeutics, Inc. (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

    Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema

    Innovation Passport provides entry to the U.K.’s Innovative Licensing and Access Pathway (ILAP), which aims to accelerate time to market and facilitate patient access to innovative medicines NTLA-2002 is a single-dose genome editing therapeutic candidate designed to prevent angioedema attacks in people with hereditary angioedema (HAE) CAMBRIDGE, Mass., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developin

    2 Risky Cathie Wood Stocks to Buy Today And Hold For 5 Years

    Both are hoping to use the latest gene editing technology to make the lucrative therapies of tomorrow.

    Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones

    Strategic priorities focus on late-stage development of its CRISPR-based medicines while continuing to expand and validate its industry-leading genome editing platformSubmit IND application in mid-2023 as part of a global pivotal study of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy; study initiation anticipated by year-end 2023Submit IND application for NTLA-2002 for the treatment of hereditary angioedema (HAE) and initiate global Phase 2 study in 1H 2023P

    Cathie Wood Has Bet Big On These 10 Stocks; Here's How They Performed In 2022

    Cathie Wood makes big bets on potential huge winners. But Ark Invest's top 10 holdings, including Tesla and Roku, tumbled in 2022.

    Cathie Wood Has Bet Big On These 10 Stocks; Here's How They're Performing

    Cathie Wood makes big bets on potential huge winners. But Ark Invest's top 10 holdings, including Tesla and Roku, have tumbled in 2022.

    Cathie Wood Is Loading Up On These 12 Stocks

    In this piece, we will take a look at the top twelve stocks that are on Cathie Wood’s radar. For more stocks, head on over to Cathie Wood Is Loading Up On These 5 Stocks. If there’s one thing that can be said for certain in today’s highly volatile environment, it’s that 2022 has not […]